Search results
Results from the WOW.Com Content Network
Intron-encoded endonuclease I-Sce I is a homing endonuclease.The enzyme is used in biotechnology as a meganuclease.It recognises an 18-base pair sequence TAGGGATAACAGGGTAAT and leaves a 4 base pair 3' hydroxyl overhang.
ERG4 or Delta(24(24(1)))-sterol reductase or Delta(24(28))-sterol reductase is an enzyme that catalyzes the last step of ergosterol biosynthesis pathway in fungi Saccharomyces cerevisiae (Baker's yeast), which 5,7,22,24(28)-ergostatetraenol converted into ergosterol.
Saccharomyces cerevisiae (/ ˌ s ɛr ə ˈ v ɪ s i. iː /) (brewer's yeast or baker's yeast) is a species of yeast (single-celled fungal microorganisms). The species has been instrumental in winemaking, baking, and brewing since ancient times.
Replication cycle of L-A helper, shown at bottom, and M28 (K28) killer viruses in S. cerevisiae. Saccharomyces cerevisiae virus L-A, also called L-A helper virus, is a member of the Totiviridae family of viruses found primarily in Saccharomyces cerevisiae. [3] Its discovery in the 1970s was the main starting point of research on yeast virology. [4]
Anti-Saccharomyces cerevisiae antibodies (ASCAs) are antibodies against antigens presented by the cell wall of the yeast Saccharomyces cerevisiae. These antibodies are directed against oligomannose sequences α-1,3 Man (α-1,2 Man α-1,2 Man) n (n = 1 or 2). [ 1 ]
Cytochrome P450-DIT2 or CYP56A1 is one of the only three P450 enzyme found in fungi baker's yeast (Saccharomyces cerevisiae), the other two are CYP51F1(ERG11) and CYP61A1(ERG5) in the ergosterol biosynthesis pathway. [1] CYP56A1 thought to catalyze the oxidation of tyrosine residues in the formation of L,L-dityrosine, a precursor of the spore ...
Saccharomycetes belongs to the Ascomycota division of the kingdom Fungi.It is the only class in the subdivision Saccharomycotina, the budding yeasts.Saccharomycetes contains a single order, Saccharomycetales.
ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains of vaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence.